The short answer
Bitter melon has not been shown to alter semaglutide absorption or effectiveness. Oral semaglutide still needs to be taken according to its fasting and separation instructions.
What this answer covers
Momordica charantia capsules versus food, juice, seeds and other extracts; semaglutide route matters.
- Supplement or preparation
- Momordica charantia
- Medication ingredient
- semaglutide
A clinical trial was not clearly positive
A small bitter-melon capsule trial found no significant improvement in HbA1c or fasting glucose on standard diabetes therapy. It did not verify semaglutide co-use.
A glucose effect is not a drug-level measurement
The trial cannot show that bitter melon changes semaglutide absorption. The semaglutide warning about delayed stomach emptying primarily concerns its effect on other oral products, not proof that bitter melon changes the drug.
Tablet timing differs from injection timing
Take a semaglutide tablet on an empty stomach in the morning with up to 4 ounces of plain water. Wait at least 30 minutes before food, drinks or another oral product, including a supplement. Weekly injections do not have this fasting or 30-minute rule.
Keep product differences in view
Capsules, juice and food are different exposures. Review the actual product and glucose response with the clinician. Neither a null trial nor a theoretical interaction establishes that every preparation is safe.
Evidence and practical considerations
Absorption & effectiveness
No exact-pair clinical evidence establishes the claimed change in semaglutide exposure, effectiveness or safety. Indirect preparation-specific findings and contrary/null results retained; general tablet administration is a separate finding.
- Exact scope
- Momordica charantia capsules versus food, juice, seeds and other extracts; semaglutide route matters. with Semaglutide RxCUI 1991302 IN; exact oral-tablet and subcutaneous formulation boundaries.
- Medication form and route
- oral medication; subcutaneous medication; oral supplement
What remains uncertain
- No supplement-specific percentage, event rate, nutrient requirement or injection gap established.
Factors that may matter: Formulation; Preparation; Insulin or sulfonylurea co-use; Gastrointestinal symptoms.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40adults with type2diabetes.
No significant improvement in HbA1c or fasting glucose with bitter-melon capsules versus placebo on standard therapy.
How this applies: Indirect for semaglutide; exact original exposure, preparation and endpoint retained.
Small capsule trial on incompletely specified standard therapy; no verified semaglutide group, drug levels or exact-pair outcomes.
Research assessment: · Open full citations ↗
Timing & monitoring
Oral semaglutide is taken fasting and at least 30 minutes before other oral products; this administration rule does not establish a botanical-specific interaction or apply to weekly injections.
- Exact scope
- Momordica charantia capsules versus food, juice, seeds and other extracts; semaglutide route matters. with Current semaglutide tablets versus injections.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Not a protective gap for all pharmacodynamic effects.
Factors that may matter: Formulation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact semaglutide article distinguishing oral administration, injected treatment and supplement-specific evidence. | |
| Research summary published |
Article revision: b3ace81b310640ab
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.